Key Highlights

Risk & Performance

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

2 recruiting

Phase 4

2(66.7%)

Phase 2

1(33.3%)

3Total

Phase 4(2)

Phase 2(1)

Loading network data...

Showing 5 of 5 trials

Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B

Role: collaborator

Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B

Role: collaborator

Clinical Safety and Efficacy of Flow-diverter in the Treatment of Intracranial Aneurysms

Role: collaborator

Stroke Registration of Young Adults in China

Role: collaborator

One Pass Tirofiban In Management of Ischemic Stroke Thrombectomy In China

Role: collaborator

All 5 trials loaded